This is a routine AGM outcome filing with no new financial data or strategic catalysts. Monitor the next earnings release or 20-F for fundamental updates. The dividend is confirmed but unchanged from prior expectations.
TAK drugs
TAK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 24 $15.72entry
- T+1 · 5mo ago −0.45%α −0.59% · $15.65
- T+5 · 5mo ago +1.46%α −0.24% · $15.95
- T+20 · 4mo ago +7.32%α +5.38% · $16.87
- T+60 · 2mo ago +21.18%α +18.35% · $19.05
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Takeda filed a 6-K reporting resolutions from its 150th Annual General Meeting of Shareholders. Key outcomes include approval of a year-end dividend of 100 JPY per share, re-election of six directors, and election of two new directors (Julie Kim and Paul Stoffels) as non-Audit and Supervisory Committee Members, plus two new ASC directors. The filing is routine governance with no material financial data or strategic changes.
Key Facts
- Year-end dividend of 100 JPY per share approved.
- Eight directors (non-ASC) re-elected or newly elected, including Julie Kim and Paul Stoffels.
- Three ASC directors re-elected or newly elected, all external.
- Director bonuses capped at 260 million JPY total for two eligible directors.
- No financial results, guidance, or material business developments disclosed.
Financial Impact
Dividend of 100 JPY per share; director bonus pool of 260 million JPY (approx. $1.7M at current rates). No revenue, earnings, or other financial figures provided.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001395064-26-000181 |
| Document: 0001395064-26-000181-index-headers.html | 0001395064-26-000181 |
| Document: 0001395064-26-000181-index.html | 0001395064-26-000181 |
| Document: 0001395064-26-000181.txt | 0001395064-26-000181 |
Track record
18 reports on TAK
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $21.19 to $21.12 Now $21.59 +1.89% ▼ −0.33% −3.62% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $20.87 to $21.09 Now $21.59 +3.45% ▲ +1.05% +0.98% vs SPY
- Oct 29, 202618d ago 6-K Neutral 4/10 No price data
- Oct 29, 202618d ago 6-K Bearish 5/10 Entry $20.01 to $21.19 Now $21.59 −7.90% ▼ −5.90% −10.62% vs SPY
- Sep 14, 20269w ago 6-K Bullish 7/10 Entry $18.60 to $18.89 Now $21.59 +16.08% ▲ +1.56% +1.45% vs SPY
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $18.24 to $17.98 Now $21.59 +18.37% ▼ −1.43% −1.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 2/10 Entry $18.13 to $18.03 Now $21.59 +19.08% ▼ −0.55% −1.67% vs SPY
- Aug 14, 202613w ago Court Ruling Neutral 4/10 Entry $17.38 to $18.24 Now $21.59 +24.22% ▲ +4.95% +6.14% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 3/10 Entry $17.39 to $18.13 Now $21.59 +24.15% ▲ +4.26% +6.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers